New England Journal of Medicine· 2018Q1

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives et al.

5,682citations
Q1SCImago
2018year

Short summary

A single infusion of anti-CD19 CAR T-cell therapy, tisagenlecleucel, achieved an 81% overall remission rate within 3 months in pediatric and young adult patients with relapsed or refractory B-cell ALL, with durable remissions observed for up to 12 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine